18F-Facbc in Prostate Cancer: A Systematic Review and Meta-Analysis

  • Cancers (Basel). 2019 Sep 11;11(9):1348. doi: 10.3390/cancers11091348.
Riccardo Laudicella  1 ,  Domenico Albano  2 ,  Pierpaolo Alongi  3 ,  Giovanni Argiroffi  4 ,  Matteo Bauckneht  5 ,  Sergio Baldari  6 ,  Francesco Bertagna  7 ,  Michele Boero  8 ,  Giuseppe De Vincentis  9 ,  Angelo Del Sole  10 ,  Giuseppe Rubini  11 ,  Lorenzo Fantechi  12 ,  Viviana Frantellizzi  13 ,  Gloria Ganduscio  14 ,  Priscilla Guglielmo  15 ,  Anna Giulia Nappi  16 ,  Laura Evangelista  17 ,  on the behalf of Young AIMN Working Group  18
Affiliations
  • 1. Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, Italy. [email protected].
  • 2. Department of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, Italy. [email protected].
  • 3. Unit of Nuclear Medicine, Fondazione Istituto G.Giglio, 90015 Cefalù, Italy. [email protected].
  • 4. Department of Health Sciences, University of Milan, 20142 Milan, Italy. [email protected].
  • 5. Nuclear Medicine Unit, IRCCS Policlinico San Martino, 16132 Genoa, Italy. [email protected].
  • 6. Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, Italy. [email protected].
  • 7. Department of Nuclear Medicine, University of Brescia and Spedali Civili Brescia, 25123 Brescia, Italy. [email protected].
  • 8. Nuclear Medicine Unit, AO Brotzu, 09134 Cagliari, Italy. [email protected].
  • 9. Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, 00161 Rome, Italy. [email protected].
  • 10. Department of Health Sciences, University of Milan, 20142 Milan, Italy. [email protected].
  • 11. Nuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70124 Bari, Italy. [email protected].
  • 12. Department of New Technologies and Translational Research in Medicine and Surgery, Nuclear Medicine Unit, University of Pisa, 56126 Pisa, Italy. [email protected].
  • 13. Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. [email protected].
  • 14. Unit of Nuclear Medicine, Fondazione Istituto G.Giglio, 90015 Cefalù, Italy. [email protected].
  • 15. Nuclear Medicine Unit, AO Brotzu, 09134 Cagliari, Italy. [email protected].
  • 16. Nuclear Medicine Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70124 Bari, Italy. [email protected].
  • 17. Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS, 35128 Padua, Italy. [email protected].
  • 18. Department of Biomedical and Dental Sciences and of Morpho-functional Imaging, Nuclear Medicine Unit, University of Messina, 98125 Messina, Italy.
PMID: 31514479 DOI: 10.3390/cancers11091348
Abstract

Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid (anti-[18F]-FACBC) has been approved for the detection of prostate Cancer (PCa) in patients with elevated prostate-specific-antigen following prior treatment. This review and meta-analysis aimed to investigate the diagnostic performance of 18F-FACBC positron emission tomography/computed-tomography (PET/CT) in the detection of primary/recurrent PCa. A bibliographic search was performed including several databases, using the following terms: "FACBC"/"fluciclovine" AND "prostate cancer"/"prostate" AND "PET"/"Positron Emission Tomography". Fifteen and 9 studies were included in the systematic reviews and meta-analysis, respectively. At patient-based analysis, the pooled sensitivity and specificity of 18F-FACBC-PET/CT for the assessment of PCa were 86.3% and 75.9%, respectively. The pooled diagnostic odds-ratio value was 16.453, with heterogeneity of 30%. At the regional-based-analysis, the pooled sensitivity of 18F-FACBC-PET/CT for the evaluation of primary/recurrent disease in the prostatic bed was higher than in the extra-prostatic regions (90.4% vs. 76.5%, respectively); conversely, the pooled specificity was higher for the evaluation of extra-prostatic region than the prostatic bed (89% vs. 45%, respectively). 18F-FACBC-PET/CT seems to be promising in recurrent PCa, particularly for the evaluation of the prostatic bed. Additional studies to evaluate its utility in clinical routine are mandatory.

Keywords
18F-FACBC; PET/CT; meta-analysis; prostate cancer; recurrence; review.
Products